Stages of the clinical course of schizophrenia - staging concept

Wójciak, Paweł; Remlinger-Molenda, Agnieszka; Rybakowski, Janusz

doi:10.12740/pp/58723

Cited by 15 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other authors have proposed 3 to 8 stages based on the development of the illness over time (Agius et al, 2010; McGorry et al, 2010). The main idea is that clinical staging could permit better targeting of treatment and could also significantly improve the individualized balance of potential risks and benefits (Wojciak et al, 2016). In spite of these pressing needs, to date there is no easily applicable and reliable clinical tool available for the identification of stages in patients with schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Fountoulakis

Dragioti²,

Antonis

et al. 2019

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

IntroductionA specific clinically relevant staging model for schizophrenia has not yet been developed. The aim of the current study was to evaluate the factor structure of the PANSS and develop such a staging method.MethodsTwenty-nine centers from 25 countries contributed 2358 patients aged 37.21 ± 11.87 years with schizophrenia. Analysis of covariance, Exploratory Factor Analysis, Discriminant Function Analysis, and inspection of resultant plots were performed.ResultsExploratory Factor Analysis returned 5 factors explaining 59% of the variance (positive, negative, excitement/hostility, depression/anxiety, and neurocognition). The staging model included 4 main stages with substages that were predominantly characterized by a single domain of symptoms (stage 1: positive; stages 2a and 2b: excitement/hostility; stage 3a and 3b: depression/anxiety; stage 4a and 4b: neurocognition). There were no differences between sexes. The Discriminant Function Analysis developed an algorithm that correctly classified >85% of patients.DiscussionThis study elaborates a 5-factor solution and a clinical staging method for patients with schizophrenia. It is the largest study to address these issues among patients who are more likely to remain affiliated with mental health services for prolonged periods of time.

show abstract

Section: Introductionmentioning

confidence: 99%

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Fountoulakis

Dragioti²,

Antonis

et al. 2019

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…On the other hand, a prodromal phase for SZ has been described. It entails the deterioration of cognitive function and precedes an emerging psychotic episode 27. Thus, interventions during this phase have been suggested as strategies to reduce the transition to psychosis 28.…”

Section: Discussionmentioning

confidence: 99%

<p>Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population</p>

Cruz

Juárez‐Rojop

Tovilla-Zárate

et al. 2019

NDT

View full text Add to dashboard Cite

Background Circulating cell-free mitochondrial DNA (cf-mtDNA) fragments in blood plasma have been reported in patients with schizophrenia (SZ). Although the relationship of cf-mtDNA to the cognitive status of patients with SZ has not yet been explored, it is known that cognitive impairment in SZ compromises the functional and social capacity of these patients and diminishes their quality of life. In this sense, the assessment of the severity of cognitive impairment in a Mexican population with SZ and its association with cf-mtDNA levels in blood plasma may provide the possibility of using cf-mtDNA as a biomarker to determine the status of the disease and the possible ensuing changes over time. Methods Subjects for a case–control study will be recruited. cf-mtDNA obtained from blood plasma will be quantified by real-time polymerase chain reaction, using melting curve technology with SYBR green as amplification marker. Patients with SZ will be grouped into those with severe, mild, and no cognitive impairment according to Montreal Cognitive Assessment scale scores, to determine differences between cognitive performance and cf-mtDNA levels in blood plasma. Ethics and communication This study has been approved by the ethics and investigation committees of the High Specialty Regional Hospital of Mental Health (Hospital Regional de Alta Especialidad de Salud Mental); project No. HRAESM/DG/RP/1128/2018. We plan to communicate our research findings in scientific conferences and in peer-reviewed journals. Conclusion It is known that cognitive dysfunction provokes negative effects in an SZ patient´s life. This project aims to provide better knowledge about the role of cf-mtDNA in the pathogenesis of cognitive impairment in SZ, as an attempt to achieve improvements to the existing treatments, thereby helping to prevent major cognitive deterioration.

show abstract

“…Populasi terjangkau adalah pasien skizofrenia kronik yang dirawat di RSJD dr. Amino Gondohutomo Semarang pada periode penelitian. Subjek penelitian meliputi pasien skizofrenia rawat inap dengan lama sakit minimal 2 tahun 7 , mendapat pengobatan psikotropika dengan atau tanpa tambahan anti kolinergik, usia 20 -50 tahun, minimal lulus SD dan keluarga memberikan consent penelitian. Kriteria eksklusi jika memiliki gangguan medik umum dan atau komorbid lain, terdapat riwayat penggunaan zat dan alkohol yang diketahui dari wawancara dan memakai obat anti epilepsi.…”

Section: Metodeunclassified

Pengaruh Pemberian Ajuvan Asam Folat Terhadap Fungsi Personal Dan Sosial Pasien Skizofrenia Kronik

Suprapti

Fitrikasari

Pudjo³

et al. 2021

Journal of Nutrition College

View full text Add to dashboard Cite

Latar Belakang : Hasil pengobatan skizofenia menunjukkan sebanyak 85% mengalami penurunan fungsi. Remisi klinis tidak selalu mengarah pada pemulihan fungsi. Defisiensi folat diidentifikasi sebagai salah satu faktor risiko skizofrenia.Tujuan : Mengetahui manfaat ajuvan asam folat dalam memperbaiki fungsi personal dan sosial pasien skizofrenia kronis.Metode : Penelitian eksperimental dengan desain double blind – randomized controlled trial, pre post test design. Semua subjek yang memenuhi kriteria inklusi diambil menurut waktu (consecutive sampling), kemudian secara blok random dikelompokkan dalam kelompok perlakuan dan kelompok kontrol. Perlakuan dengan ajuvan asam folat 2 mg / hari selama 4 minggu. Kelompok kontrol mendapatkan anti psikotik dengan plasebo. Anti psikotik yang digunakan tidak sama. PSP diukur sebelum dan sesudah perlakuan. Instrumen penelitian menggunakan kuesioner sosiodemografi dan kuesioner wawancara terstruktur Personal and Social Performance Scale versi Indonesia.Hasil : Terdapat 66 subjek yang memenuhi kriteria inklusi, 2 diantaranya Drop Out karena kejang dan SNM. Uji komparatif karakteristik demografik kelompok perlakuan dan kelompok kontrol tidak ada perbedaan bermakna. Terdapat peningkatan skor PSP yang bermakna secara statistik p <0,01 di kedua kelompok dengan peningkatan skor PSP kelompok perlakuan lebih tinggi (p = 0,029).Simpulan : Ajuvan asam folat memperbaiki fungsi sosial dan personal pasien skizofrenia kronis.

show abstract

Stages of the clinical course of schizophrenia - staging concept

Cited by 15 publications

References 0 publications

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study

<p>Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population</p>

Pengaruh Pemberian Ajuvan Asam Folat Terhadap Fungsi Personal Dan Sosial Pasien Skizofrenia Kronik

Contact Info

Product

Resources

About